In addition, since several states and territories in the US have adopted the GALT mutation analysis as a second-tier test, it may be useful to expand the scope to other galactosemia-associated genes, including GALM, as another possible extension of neonatal screening for galactosemia. This evidence concerns the gene GALT and galactosemia.